Ruth Bailey
Psychiatric/Mental Health · Columbus, INNPI 1659845139
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 392 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 11.6% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 392 payments — averaging $16.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$752
- Supernus Pharmaceuticals, Inc.$747
- Johnson & Johnson$652
- Vanda Pharmaceuticals Inc.$620
- Neurocrine Biosciences, Inc.$452
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$439
- plus $3K from 19 others
What the payments were for
- Travel & lodging$180%
- Food & beverage$6,27797%
- Education$1612%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 57 | $752 |
| Supernus Pharmaceuticals, Inc. | 59 | $747 |
| Johnson & Johnson | 32 | $652 |
| Vanda Pharmaceuticals Inc. | 31 | $620 |
| Neurocrine Biosciences, Inc. | 32 | $452 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 23 | $439 |
| Alkermes, Inc. | 26 | $405 |
| Otsuka America Pharmaceutical, Inc. | 23 | $378 |
| Ironshore Pharmaceuticals Inc. | 11 | $324 |
| Axsome Therapeutics, Inc. | 14 | $314 |
| Teva Pharmaceuticals USA, Inc. | 18 | $301 |
| Lundbeck LLC | 11 | $204 |
| Indivior Inc. | 12 | $195 |
| Sunovion Pharmaceuticals Inc. | 8 | $108 |
| Idorsia Pharmaceuticals US Inc | 7 | $107 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $87 |
| Collegium Pharmaceutical, Inc. | 4 | $82 |
| Corium, LLC | 8 | $81 |
| E.r. Squibb & Sons, L.L.C. | 4 | $66 |
| Gilead | 2 | $48 |
| Braeburn Inc. | 2 | $29 |
| Almatica Pharma LLC | 1 | $23 |
| Exact Sciences | 1 | $15 |
| Eisai Inc. | 1 | $15 |
| Noven Therapeutics, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JORNAY PM$150
- QELBREE$143
- VRAYLAR$122
- Fanapt$113
- ABILIFY MAINTENA$102
How this compares
$6,456 in reported general payments places this provider in the 90th percentile of 729 psychiatric/mental health providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 88 | $278,417 |
| RexultiBrexpiprazole | 92 | $157,727 |
| VraylarCariprazine Hcl | 90 | $124,260 |
| IngrezzaValbenazine Tosylate | 14 | $111,617 |
| LybalviOlanzapine/Samidorphan Malate | 32 | $53,273 |
| Abilify MaintenaAripiprazole | 15 | $42,593 |
| CaplytaLumateperone Tosylate | 23 | $40,954 |
| AuvelityDextromethorphan Hbr/Bupropion | 38 | $40,865 |
| TrintellixVortioxetine Hydrobromide | 39 | $29,181 |
| FanaptIloperidone | 16 | $27,202 |
| Aripiprazole | 92 | $10,640 |
| Paliperidone ErPaliperidone | 50 | $8,980 |
| Lurasidone Hcl | 46 | $7,994 |
| VyvanseLisdexamfetamine Dimesylate | 20 | $7,554 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 25 | $5,597 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $652 | $278,41788 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $378 | $200,320107 claims |
| AbbVieVraylar | $752 | $124,26090 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $452 | $111,61714 claims |
| Alkermes, Inc.Lybalvi | $405 | $53,27332 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $439 | $40,95423 claims |
| Axsome Therapeutics, Inc.Auvelity | $314 | $40,86538 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $87 | $36,73559 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $620 | $27,20216 claims |
| Teva Pharmaceuticals USA, Inc.Loxapine | $301 | $98644 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 729 psychiatric/mental health providers in Indiana.
Other psychiatric/mental health in Columbus
- Lauren LutzColumbus$320K
- Brooke KempfTerre Haute$1.1M
- Gerald LewisMerrillville$336K
- Sonya RuedlingerIndianapolis$134K
- Trina GreenwaldMarion$107K
- Paul DuncanJeffersonville$46K
- Morgan StamperConnersville$42K
- Jennifer JimenezUnion Mills$37K
- Savannah MullinsClarksville$31K
- Sharon ClevengerFort Wayne$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.